ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.

MLA

Currier, Judith S., et al. “ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.” Journal of Infectious Diseases, vol. 288, Sept. 2023, pp. S77–82. EBSCOhost, https://doi.org/10.1093/infdis/jiad246.

APA

Currier, J. S., Moser, C., Eron, J. J., Chew, K. W., Smith, D. M., Javan, A. C., Wohl, D. A., Daar, E. S., Hughes, M. D., & Team, for the A.-2/A5401 S. (2023). ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients. Journal of Infectious Diseases, 288, S77–S82. https://doi.org/10.1093/infdis/jiad246

Chicago

Currier, Judith S, Carlee Moser, Joseph J Eron, Kara W Chew, Davey M Smith, Arzhang Cyrus Javan, David Alain Wohl, Eric S Daar, Michael D Hughes, and for the ACTIV-2/A5401 Study Team. 2023. “ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.” Journal of Infectious Diseases 288 (September): S77–82. doi:10.1093/infdis/jiad246.